A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies
Sara M. Federico, Alberto S. Pappo, Natasha Sahr, April Sykes, Olivia Campagne, Clinton F. Stewart, Michael R. Clay, Armita Bahrami, Mary B. McCarville, Sue C. Kaste, Victor M. Santana, Sara Helmig, Jessica Gartrell, Anang A. Shelat, Rachel C. Brennan, Dana Hawkins, Kimberly Godwin, Michael W. Bishop, Wayne L. Furman, Elizabeth Stewart
Topics & Concepts
IrinotecanMedicineNeutropeniaTemozolomideSarcomaInternal medicineFebrile neutropeniaRefractory (planetary science)Phases of clinical researchSurgeryGastroenterologyOncologyResponse Evaluation Criteria in Solid TumorsCancerChemotherapyPathologyColorectal cancerPhysicsAstrobiologyPARP inhibition in cancer therapyNeuroblastoma Research and TreatmentsCancer therapeutics and mechanisms